Rating History for Relmada Therapeutics Inc (RLMD) by Lucid Capital Markets
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 3/2/2026 | Christopher Liu | New Coverage | Buy (N/A) |
14.00 (N/A) |
4.56 (6.33) |
38.82% | Details |
